The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys

Scott J. Webster, Christina A Wilson, Chih Hung Lee, Eric G. Mohler, Alvin V Terry, Jerry J. Buccafusco

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BACKGROUND Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non-human primates, young adult (11-17 years old) and aged (20-31 years old) rhesus macaques. EXPERIMENTAL APPROACH The effects of dimebolin (3.9-118 μg kg -1) on working memory, as measured by performance on delayed matching-to-sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer-assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 min before a cognitively-impairing dose (20 μg kg -1) of scopolamine. KEY RESULTS In both the young adult and aged monkeys, dimebolin significantly increased the DMTS task accuracies. In young adults, the task improvement was associated with long (retention/retrieval) delay trials, and a protracted enhancement was observed for sessions run 24 h post administration of a single dose. Dimebolin did not significantly attenuate the scopolamine-induced impairment. In the aged monkeys, dimebolin significantly improved the reduced task accuracies associated with long delay intervals. CONCLUSIONS AND IMPLICATIONS Here we demonstrated that dimebolin is able to improve components of working memory in monkeys and to induce a protracted response for at least 24 h after administration of a single dose.

Original languageEnglish (US)
Pages (from-to)970-978
Number of pages9
JournalBritish Journal of Pharmacology
Volume164
Issue number3
DOIs
StatePublished - Oct 1 2011

Fingerprint

Macaca mulatta
Short-Term Memory
Alzheimer Disease
Haplorhini
Young Adult
Therapeutics
Scopolamine Hydrobromide
latrepirdine
Cognition
Primates
Clinical Trials

Keywords

  • cognitive
  • dimebolin
  • drug
  • monkey
  • operant

ASJC Scopus subject areas

  • Pharmacology

Cite this

The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. / Webster, Scott J.; Wilson, Christina A; Lee, Chih Hung; Mohler, Eric G.; Terry, Alvin V; Buccafusco, Jerry J.

In: British Journal of Pharmacology, Vol. 164, No. 3, 01.10.2011, p. 970-978.

Research output: Contribution to journalArticle

Webster, Scott J. ; Wilson, Christina A ; Lee, Chih Hung ; Mohler, Eric G. ; Terry, Alvin V ; Buccafusco, Jerry J. / The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. In: British Journal of Pharmacology. 2011 ; Vol. 164, No. 3. pp. 970-978.
@article{a01c70be48d34e34ab6859d7c914dc99,
title = "The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys",
abstract = "BACKGROUND Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non-human primates, young adult (11-17 years old) and aged (20-31 years old) rhesus macaques. EXPERIMENTAL APPROACH The effects of dimebolin (3.9-118 μg kg -1) on working memory, as measured by performance on delayed matching-to-sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer-assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 min before a cognitively-impairing dose (20 μg kg -1) of scopolamine. KEY RESULTS In both the young adult and aged monkeys, dimebolin significantly increased the DMTS task accuracies. In young adults, the task improvement was associated with long (retention/retrieval) delay trials, and a protracted enhancement was observed for sessions run 24 h post administration of a single dose. Dimebolin did not significantly attenuate the scopolamine-induced impairment. In the aged monkeys, dimebolin significantly improved the reduced task accuracies associated with long delay intervals. CONCLUSIONS AND IMPLICATIONS Here we demonstrated that dimebolin is able to improve components of working memory in monkeys and to induce a protracted response for at least 24 h after administration of a single dose.",
keywords = "cognitive, dimebolin, drug, monkey, operant",
author = "Webster, {Scott J.} and Wilson, {Christina A} and Lee, {Chih Hung} and Mohler, {Eric G.} and Terry, {Alvin V} and Buccafusco, {Jerry J.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1111/j.1476-5381.2011.01432.x",
language = "English (US)",
volume = "164",
pages = "970--978",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys

AU - Webster, Scott J.

AU - Wilson, Christina A

AU - Lee, Chih Hung

AU - Mohler, Eric G.

AU - Terry, Alvin V

AU - Buccafusco, Jerry J.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - BACKGROUND Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non-human primates, young adult (11-17 years old) and aged (20-31 years old) rhesus macaques. EXPERIMENTAL APPROACH The effects of dimebolin (3.9-118 μg kg -1) on working memory, as measured by performance on delayed matching-to-sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer-assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 min before a cognitively-impairing dose (20 μg kg -1) of scopolamine. KEY RESULTS In both the young adult and aged monkeys, dimebolin significantly increased the DMTS task accuracies. In young adults, the task improvement was associated with long (retention/retrieval) delay trials, and a protracted enhancement was observed for sessions run 24 h post administration of a single dose. Dimebolin did not significantly attenuate the scopolamine-induced impairment. In the aged monkeys, dimebolin significantly improved the reduced task accuracies associated with long delay intervals. CONCLUSIONS AND IMPLICATIONS Here we demonstrated that dimebolin is able to improve components of working memory in monkeys and to induce a protracted response for at least 24 h after administration of a single dose.

AB - BACKGROUND Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non-human primates, young adult (11-17 years old) and aged (20-31 years old) rhesus macaques. EXPERIMENTAL APPROACH The effects of dimebolin (3.9-118 μg kg -1) on working memory, as measured by performance on delayed matching-to-sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer-assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 min before a cognitively-impairing dose (20 μg kg -1) of scopolamine. KEY RESULTS In both the young adult and aged monkeys, dimebolin significantly increased the DMTS task accuracies. In young adults, the task improvement was associated with long (retention/retrieval) delay trials, and a protracted enhancement was observed for sessions run 24 h post administration of a single dose. Dimebolin did not significantly attenuate the scopolamine-induced impairment. In the aged monkeys, dimebolin significantly improved the reduced task accuracies associated with long delay intervals. CONCLUSIONS AND IMPLICATIONS Here we demonstrated that dimebolin is able to improve components of working memory in monkeys and to induce a protracted response for at least 24 h after administration of a single dose.

KW - cognitive

KW - dimebolin

KW - drug

KW - monkey

KW - operant

UR - http://www.scopus.com/inward/record.url?scp=80052559894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052559894&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01432.x

DO - 10.1111/j.1476-5381.2011.01432.x

M3 - Article

C2 - 21486290

AN - SCOPUS:80052559894

VL - 164

SP - 970

EP - 978

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -